Stockreport

Viracta Therapeutics Provides Clinical Update and Outlook for 2024 [Yahoo! Finance]

Viracta Therapeutics, Inc.  (VIRX) 
PDF Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mid-2024 Enrollment underway in [Read more]